These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Comparison of the protective efficacy between single and combination of recombinant adenoviruses expressing complete and truncated glycoprotein, and nucleoprotein of the pathogenic street rabies virus in mice. Kim HH, Yang DK, Nah JJ, Song JY, Cho IS. Virol J; 2017 Jun 24; 14(1):122. PubMed ID: 28646885 [Abstract] [Full Text] [Related]
29. Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein. Loza-Rubio E, Rojas-Anaya E, López J, Olivera-Flores MT, Gómez-Lim M, Tapia-Pérez G. Vaccine; 2012 Aug 10; 30(37):5551-6. PubMed ID: 22749836 [Abstract] [Full Text] [Related]
30. A chimpanzee adenoviral vector-based rabies vaccine protects beagle dogs from lethal rabies virus challenge. Wang X, Fang Z, Xiong J, Yang K, Chi Y, Tang X, Ma L, Zhang R, Deng F, Lan K, Zhou D. Virology; 2019 Oct 10; 536():32-38. PubMed ID: 31394410 [Abstract] [Full Text] [Related]
31. Control of rabies in wildlife. Winkler WG, Bögel K. Sci Am; 1992 Jun 10; 266(6):86-92. PubMed ID: 1585150 [No Abstract] [Full Text] [Related]
32. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC. Virology; 1994 Feb 15; 199(1):132-40. PubMed ID: 8116236 [Abstract] [Full Text] [Related]
33. Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus. Luo J, Shi H, Tan Y, Niu X, Long T, Zhao J, Tian Q, Wang Y, Chen H, Guo X. Vaccine; 2016 Aug 17; 34(37):4392-8. PubMed ID: 27449079 [Abstract] [Full Text] [Related]
34. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Tims T, Briggs DJ, Davis RD, Moore SM, Xiang Z, Ertl HC, Fu ZF. Vaccine; 2000 Jun 15; 18(25):2804-7. PubMed ID: 10812222 [Abstract] [Full Text] [Related]
35. Rhabdovirus-based vaccine platforms against henipaviruses. Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ. J Virol; 2015 Jan 15; 89(1):144-54. PubMed ID: 25320306 [Abstract] [Full Text] [Related]
36. Rabies vaccine development by expression of recombinant viral glycoprotein. Astray RM, Jorge SA, Pereira CA. Arch Virol; 2017 Feb 15; 162(2):323-332. PubMed ID: 27796547 [Abstract] [Full Text] [Related]
37. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. J Virol; 2011 Oct 15; 85(20):10605-16. PubMed ID: 21849459 [Abstract] [Full Text] [Related]